Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
Company to Host Conference Call, May 13, 2021, at 4:30 p.m. ETLOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for ...
GlobeNewswire · 23h ago
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs.
Benzinga · 04/30 09:22
Capricor shares rise on license agreement with Johns Hopkins University
Capricor Therapeutics shares climb ([[CAPR]] +6.3%) after signing an exclusive, worldwide licensing agreement with Johns Hopkins University ((JHU)) to include engineered exosomes for vaccines and therapeutics as part of the company’s exosome
Seekingalpha · 04/29 15:54
Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact
Benzinga · 04/29 15:51
Galera Therapeutics, Ocular Therapeutix leads healthcare gainers; Adverum Biotechnologies, Cara Therapeutics among major losers
Gainers: Galera Therapeutics (GRTX) +26%, Ocular Therapeutix (OCUL) +17%, Capricor Therapeutics (CAPR) +15%, AtriCure (ATRC) +12%, Atossa Therapeutics (ATOS) +14%.Losers: Adverum Biotechnologies (ADVM) -60%, Cara Therapeutics (CARA) -44%, Regional Health P...
Seekingalpha · 04/29 15:06
Why Is Capricor Therapeutics Trading Higher Today?
Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher after the company announced it signed an exclusive, worldwide licensing agreement with Johns Hopkins University to expand its exosome platform technology portfolio.
Benzinga · 04/29 14:45
Capricor Therapeutics Enters License Deal With Johns Hopkins University to Add Engineered Exosomes to Technology Portfolio
MT Newswires · 04/29 13:06
FB, QCOM, NOK and VER among premarket gainers
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Plur...
Seekingalpha · 04/29 12:26
Capricor Therapeutics Signs Exclusive Worldwide License Agreement With Johns Hopkins University To Include Engineered Exosomes For Vaccines And Therapeutics As Part Of The Company's Exosome Technology Portfolio; Financial Details Not Disclosed
 Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases,
Benzinga · 04/29 12:06
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
-Portfolio Will Now Include Exclusive Rights to Engineered Exosomes for Vaccines and Therapeutics-LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cel...
GlobeNewswire · 04/29 12:00
Cell Therapy Market Size 2021 with a CAGR of 23.27%, Research by Business Opportunities, Top Companies data report covers are Dendreon, Mesoblast, Vericel
Apr 29, 2021 (The Expresswire) -- In 2021, “ Cell Therapy Market “ Size, Status and Market Insights, About Cell Therapy Cell therapy products, which are...
The Express Wire · 04/29 06:05
Exosome Diagnostics and Therapeutics Market Share, Size 2021 Industry Demand, Global Trend, Industry News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2025
The Express Wire · 04/27 05:48
Myocardial Infarction Drug Market 2021-2026 Global Industry Growth Opportunities, Share Estimation, Strategy, Benefits, Demand, Manufactures Analysis and Regional Forecast
Apr 26, 2021 (The Expresswire) -- The report provides revenue of the globalMyocardial Infarction Drug Market for the period 2016 and 2026, considering 2020...
The Express Wire · 04/26 04:40
Dilated Cardiomyopathy Therapeutic Market Growth Improvement Highly Witness | AstraZeneca, Pfizer, t2cure, Vericel
Apr 23, 2021 (Market Insight Reports) -- Latest released the research study on Global Dilated Cardiomyopathy Therapeutic Market, offers a detailed overview...
Market Insight Reports · 04/23 16:13
Clinical Trials Market to Witness US$ 69.7 Billion Revenue by 2030
Apr 22, 2021 (Market Stats News via COMTEX) -- The global Clinical Trials marketsize is expected to be worth around US$ 69.7 billion by 2030 from US$ 44.3...
Market Stats News · 04/22 11:21
Exosome Diagnostic and Therapeutics Market 2021:Rapid Growth,Size,Share,Industry Trends,Covid-19 Impact Analysis By Thermo Fisher Scientific, Inc., NanoSomix, Inc., NX PHARMAGEN
Apr 20, 2021 (MARKITWIRED via COMTEX) -- Future Market Insights in its recent research report titled "Exosome Diagnostic and Therapeutics Market: Global...
Markitwired · 04/20 08:18
Global Cell Therapy Market Size 2021 to 2026 Report Includes Brief Analysis by Regions, Growth Key Factors, Demand, Business Share
Apr 19, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" “Cell Therapy Market” report provides a...
The Express Wire · 04/19 07:26
Global Dilated Cardiomyopathy Market 2020 Status and Outlook, Industry Growth Rate, Opportunities and Challenges to 2026
Apr 18, 2021 (CDN Newswire via Comtex) -- Newly added by study on Global Dilated Cardiomyopathy Market Growth (Status and Outlook)...
CDN Newswire · 04/18 22:10
Clinical Trials Market Worth $ 69.7 Billion By 2028
Market Stats News · 04/15 11:36
Webull provides a variety of real-time CAPR stock news. You can receive the latest news about Capricor through multiple platforms. This information may help you make smarter investment decisions.
About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.